GH Research PLC (NASDAQ:GHRS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Posted by Brenda Bartman on Jun 7th, 2026

Shares of GH Research PLC (NASDAQ:GHRS – Get Free Report) have earned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $40.3750.

Several research analysts recently weighed in on the stock. Cantor Fitzgerald boosted their price target on shares of GH Research from $25.00 to $35.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Citizens Jmp decreased their target price on GH Research from $42.00 to $39.00 and set a “market outperform” rating for the company in a research report on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a research note on Tuesday, April 21st. HC Wainwright dropped their target price on shares of GH Research from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Finally, Citigroup reiterated an “outperform” rating on shares of GH Research in a research note on Friday, May 15th.

Get Our Latest Stock Analysis on GH Research

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC grew its stake in GH Research by 63.4% during the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after acquiring an additional 822 shares in the last quarter. North Star Investment Management Corp. purchased a new stake in GH Research in the first quarter valued at approximately $31,000. Royal Bank of Canada lifted its position in GH Research by 43.1% during the first quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock valued at $36,000 after purchasing an additional 780 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of GH Research during the 4th quarter worth $38,000. Finally, Osaic Holdings Inc. boosted its holdings in shares of GH Research by 63.6% in the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after purchasing an additional 2,400 shares in the last quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Trading Down 7.8%

GH Research stock opened at $21.43 on Friday. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -23.29 and a beta of 1.31. GH Research has a 1-year low of $11.32 and a 1-year high of $25.94. The firm’s fifty day moving average price is $19.54 and its two-hundred day moving average price is $16.48.

GH Research (NASDAQ:GHRS – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). On average, research analysts forecast that GH Research will post -1.46 EPS for the current year.

About GH Research

(Get Free Report)

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.